Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer

S Suzuki1,2, T Akechi1, M Kobayashi3, K Taniguchi1, K Goto4, S Sasaki5, S Tsugane3, Y Nishiwaki4, H Miyaoaka2 and Y Uchitomi*1,4

1Psycho-Oncology Division, National Cancer Center Research Institute East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan; 2Department of Psychiatry, Kitasato University, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan; 3Epidemiology and Biostatistics Division, National Cancer Center Research Institute East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan; 4Thoracic Oncology Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan; 5National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8636, Japan

The aim of the present study was to examine the association between daily omega-3 fatty acid intake and depression in Japanese cancer patients. Omega-3 fatty acid intake in 771 patients with newly diagnosed primary lung cancer was evaluated using a food-frequency questionnaire, and the prevalence of depression was examined using the cutoff values for the depression subscale included in the Hospital Anxiety and Depression Scale. After adjustment for potential confounding factors, the odds ratio (OR) for depression among patients in the highest quartile of the total eicosapentaenoic acid- (C20:5n-3) and docosapentaenoic acid (C22:6n-3)-intake group compared with patients in the lowest quartile was not significantly different. On the other hand, the OR among the highest quartile of α-linolenic acid (C18:3n-3)-intake (adjusted OR = 0.50, 95% CI: 0.31–0.71, P for trend = 0.004) and the highest quartile of total omega-3 fatty acid intake (adjusted OR = 0.55, 95% CI: 0.35–0.88, P for trend = 0.022) were significantly different. These results suggest that total eicosapentaenoic acid and docosapentaenoic acid intake might not be associated with depression in Japanese patients with newly diagnosed lung cancer, but that α-linolenic acid intake and total omega-3 fatty acid intake might be.

British Journal of Cancer (2004) 90, 787–793. doi:10.1038/sj.bjc.6601621 www.bjcancer.com © 2004 Cancer Research UK

Keywords: omega-3 fatty acid; α-linolenic acid; depression; lung cancer; cross-sectional study

Depression is the most common psychiatric problem in clinical oncology settings, with around 20% of cancer patients experiencing depression (McDaniel et al., 1995; Massie and Popkin, 1998). Depression influences the quality of life of cancer patients and often leads to a poor compliance with cancer treatment and suicidal ideation or suicide (Grassi et al., 1996; Breitbart et al., 2000; Colleoni et al., 2000; Akechi et al., 2002). Antidepressants are the only well-established treatment for depression in cancer patients (Gill and Hatcher, 1999); however, antidepressant therapy is difficult to perform in cancer patients, because the adverse effects of antidepressants might overload the patient’s physical condition (Akizuki et al., 2002). Thus, a novel medication with few adverse effects is needed for the management of depression in cancer patients.

Recent psychiatry studies have investigated the association between depression and omega-3 fatty acids (ω-3 FAs), a potentially natural and tolerable antidepressant. Omega-3 fatty acids, which have a double bond at the third carbon from the methyl end of the molecule, include eicosapentaenoic acid (EPA; C20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), which are derived from fish and seafood, and α-linolenic acid (α-LA; C18:3n-3), which is derived from plant sources. Humans lack the desaturase enzyme, so ω-3 FAs cannot be formed in the body; thus, dietary intake is the only source of ω-3 FAs. The depletion of cell membrane ω-3 FAs has been hypothesised to be of aetiologic importance in depression (Smith, 1991; Hibbeln and Salem, 1995; Maes and Smith, 1998).

Some clinical evidence has supported the hypothesis that low levels of ω-3 FAs may be implicated in depression. Epidemiological findings linking depression and low levels of fish intake have been reported (Hibbeln, 1998; Tanskanen et al., 2001), and biochemical research has also shown that the concentrations of each ω-3 FA are significantly lower in the serum or red blood cell membranes of depressed patients than in control subjects (Edwards et al., 1998; Peet et al., 1998; Maes et al., 1999). Ethyl-EPA augmentation therapy has been reported to improve depressive symptoms in patients with major depression in randomised placebo-controlled double-blind clinical trials (Nemets et al., 2002; Peet and Horrobin, 2002) and in one clinical report (Puri et al., 2002). These trials have also reported no or a few adverse effects of the medication (e.g. mild gastrointestinal tract distress). In addition, the antidepressive effect of ω-3 FAs has also been reported in patients with other psychiatric conditions, including depression in pregnant women (Chiu et al., 2003), borderline personality disorder (Zanarini and Frankenburg, 2003), and bipolar disorder (Stoll et al., 1999). This clinical evidence suggests that the administration of ω-3 FAs, especially EPA or DHA, may be useful for the management of depression in various situations.
As a preliminary examination of the utility of administering \( \omega-3 \) FAs for the treatment or prevention of depression in cancer patients, we performed a cross-sectional study on the relationship between the daily intake of each \( \omega-3 \) FA (as calculated using a food-frequency questionnaire (FFQ)) and the prevalence of depression in newly diagnosed Japanese patients with lung cancer. We hypothesised that a high intake of EPA and DHA may be associated with a low prevalence of depression.

METHODS

Subjects

This study was approved by the Institutional Review Board and the Ethics Committee of the National Cancer Center, Japan. Data from subjects who participated in The Lung Cancer Database Project at the National Cancer Center Hospital East and the National Cancer Center Research Institute East were used in the present study. The aim of The Lung Cancer Database Project is to construct a comprehensive database of information that can be used to investigate the pathogenesis of lung cancer and improve currently available treatments. The database includes information on demographic factors, physical symptoms, psychological factors, and lifestyle factors (diet, smoking, etc) obtained from self-reported questionnaires and medical information from the patients’ medical charts and blood, DNA, and urine specimens.

The subjects enrolled in the present study were all newly diagnosed patients with primary lung cancer, who visited the Thoracic Oncology Division of the National Cancer Center Hospital East, Japan. Patients were included in this database study if they met all of the following criteria: informed of their lung cancer diagnosis; lung cancer diagnosis confirmed by histological examination; physically capable of completing the questionnaires; absence of cognitive impairments such as dementia and delirium; ability to provide written consent; no problems regarding the patients’ participation in this database study, as judged by their physicians.

Study procedure

Between July 1999 and November 2001, consecutive patients eligible for The Lung Cancer Database Project were recruited after the disclosure of their diagnosis by their attending physician. The patients completed the questionnaires during the waiting period prior to admission, and the questionnaires were collected after the patients completed the questionnaires during the waiting period prior to the disclosure of their diagnosis by their attending physician. The Lung Cancer Database Project at the National Cancer Center Hospital East, Japan. Patients were included in this database study if they met all of the following criteria: informed of their lung cancer diagnosis; lung cancer diagnosis confirmed by histological examination; physically capable of completing the questionnaires; absence of cognitive impairments such as dementia and delirium; ability to provide written consent; no problems regarding the patients’ participation in this database study, as judged by their physicians.

Measurement of depression

We used the Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983), which consists of a seven-item anxiety subscale and a seven-item depression subscale to assess the anxiety and depressive symptoms during the preceding week in medically ill patients. The HADS has been used as a reliable and valid method of screening for depression in patients with cancer (Razavi et al, 1990; Hopwood et al, 1991; Patrick et al, 2003). Each item is rated on a scale of 0–3, with higher scores denoting a greater mood disturbance. The reliability and validity of the Japanese version of this questionnaire has been established in Japanese cancer patients (Kugaya et al, 1998). In this study, depression was evaluated using the depression subscale (HADS-D) with a cutoff point of 4/5, since this cutoff point has been found to yield a good sensitivity and specificity (91.5 and 58.0%, respectively) (Kugaya et al, 1998) for the screening of depression (adjustment disorder and major depression).

Assessment \( \omega-3 \) FA intake

The semiquantitative FFQ was made for a population-based prospective study in Japan (Tsubono et al, 1996), and contains questions regarding 138 foods (including 18 fish and seafood items). For each food item, the participants reported the average frequency of consumption during the preceding year prior to the onset of their cancer symptoms and specified the usual serving size. Nine food items were possible for each food item, ranging from ‘never’ to ‘7 or more times per day’. The average daily intake of nutrients was calculated by multiplying the frequency of the consumption of each item by its nutrient content per serving and totalling the nutrient intake for all food items. The method used to calculate the average daily intake of each food and nutrient based on the FFQ responses has been described elsewhere (Sasaki et al, 2003).

The \( \omega-3 \) FA family includes \( \omega-3 \)-LA (C18:3n-3), octadecatetraenoic acid (C18:4n-3), eicosatetraenoic acid (C20:4n-3), EPA (C20:5n-3), docosapentaenoic acid (DPA; C22:5n-3), and DHA (22:6n-3). We calculated the intake of each of these compounds, the total EPA and DHA intake, and the total \( \omega-3 \) FA intake. The Fatty Acid Composition Table of Japanese Foods (Science and Technology Agency, Japan, 1996) was used to calculate the intake of each \( \omega-3 \) FA. Since the table has missing values for some foods, we substituted the fatty acid composition of the missing foods (Sasaki et al, 1999).

The validity of the FFQ was assessed in a random sample of 102 men and 113 women living in four areas of Japan by comparing the data from the FFQ with the data from 14–28 dietary records collected approximately 6 months apart. The Spearman rank correlation coefficients for an association between the data from the FFQ and the dietary records for the men and women were 0.26 (95% CI, 0.04 – 0.48) and 0.28 (0.13 – 0.44), for the total \( \omega-3 \) FAs intake (energy-adjusted values according to energy density), respectively, 0.32 (0.16 – 0.48) and 0.20 (0.05 – 0.34) for \( \omega-3 \)-LA intake; 0.40 (0.09–0.72) and 0.47 (0.34–0.60) for octadecatetraenoic acid intake; 0.27 (−0.06 – 0.6) and 0.30 (0.17 – 0.44) for eicosatetraenoic acid intake; 0.38 (0.09 – 0.67) and 0.41 (0.26 – 0.56) for EPA intake; 0.36 (0.05 – 0.67) and 0.35 (0.22 – 0.49) for DHA intake; and 0.34 (0.07 – 0.61) and 0.36 (0.21 – 0.51) for DHA intake.

Assessment of demographic and medical factors

Demographic factors (age, gender, education level, employment status, marital status, smoking, and drinking habits) and medical factors (histology, clinical stage, and symptoms) were obtained from the self-reported questionnaires and the patients’ medical charts. Performance status (PS) was assessed by each attending physician using the Eastern Cooperative Oncology Group criteria.

Statistical analyses

Odds ratios were calculated by dividing the prevalence of depression in each of four equal quartile groups (grouped according to the intake of each \( \omega-3 \) FA) by the prevalence of depression in the lowest quartile of \( \omega-3 \) FA intake. The same analysis was conducted using quartiles grouped according to total \( \omega-3 \) FA intake and total EPA and DHA intake. A logistic-regression analysis, with adjustments for sex and age in 10-year groupings, was then performed; simultaneously, pain (present/absent) and performance status (0/1 – 4) were used as factors well known to be strongly associated with depression in cancer patients, and smoking status (current-smoker/ex-smoker) and amount of alcohol consumption were used as factors thought to influence \( \omega-3 \) FA metabolism (Simon et al, 1996; Pawlosky and Salem, 1999). Some background variables that were significantly associated with depression in this sample, according to a bivariate analysis (\( \chi^2 \) test), were also included; histology
(small/non-small-cell carcinoma), clinical stage (Ia-IIb/IIIa-IV), breathlessness (present/absent), and employment status (employed/unemployed) (Table 1). We also tested for significant trends by assigning each patient the median value of their category and modelling it as a continuous variable.

A P-value of <0.05 was considered to be statistically significant; all tests were two-tailed. All statistical analyses were performed on a personal computer using the statistical software package SPSS for Windows (Version 11.0J, SPSS Japan Institute Inc.).

**RESULTS**

**Participants**

In total, 1013 patients with newly diagnosed, untreated primary lung cancer were admitted during The Lung Cancer Database Project enrolment period. A total of 42 patients were ineligible, the most common reason for exclusion being that the patient’s condition was too poor for the patient to participate in the project. Of the remaining 971 eligible patients, 30 refused to participate. Therefore, 941 patients were included in the analysis.

### Table 1 Patients’ characteristics

| Variable                      | HADS-Da | ≤4 (n = 335) | ≥5 (n = 436) | P-value |
|-------------------------------|---------|--------------|--------------|---------|
| Age (mean ± s.d. years)       |         | 64.0 (9.5)   | 64.3 (9.1)   | 0.651   |
| Sex                           | Female  | 93 (27.8)    | 122 (28.0)   | 0.946   |
| Education                     | ≤9 years| 101 (30.1)   | 136 (31.2)   | 0.705   |
| Marital status                | Married | 280 (83.6)   | 370 (84.9)   | 0.669   |
| Employment status             | Full & part time | 151 (45.1) | 152 (34.9) | 0.004   |
| Histology                     |         |              |              |         |
| Adenocarcinoma                |         | 221 (66.0)   | 240 (55.0)   | 0.003   |
| Squamous                      |         | 67 (20.0)    | 87 (20.0)    |         |
| Small                         |         | 20 (6.0)     | 57 (13.1)    |         |
| Large                         |         | 21 (6.3)     | 36 (8.3)     |         |
| Others                        |         | 6 (1.8)      | 16 (3.7)     |         |
| Clinical stageb               |         |              |              |         |
| la                            |         | 111 (33.1)   | 72 (16.5)    | 0.000   |
| lb                            |         | 59 (17.6)    | 64 (14.7)    |         |
| ilb                           |         | 4 (1.2)      | 7 (1.6)      |         |
| Ila                           |         | 15 (4.5)     | 28 (6.4)     |         |
| IIIb                          |         | 19 (5.7)     | 42 (9.6)     |         |
| IV                            |         | 49 (14.6)    | 93 (21.3)    |         |
| Performance statusc           |         |              |              |         |
| 0                             |         | 168 (50.1)   | 141 (32.3)   | 0.000   |
| 1                             |         | 161 (48.1)   | 261 (59.9)   |         |
| 2                             |         | 6 (1.8)      | 24 (5.5)     |         |
| 3                             |         | 0 (0.0)      | 10 (2.3)     |         |
| 4                             |         | 0 (0.0)      | 0 (0.0)      |         |
| Symptoms                      |         |              |              |         |
| Breathlessness (presence)     |         | 102 (30.4)   | 226 (51.8)   | 0.000   |
| Pain (presence)               |         | 86 (25.7)    | 176 (41.4)   | 0.000   |
| Smoking                       |         |              |              |         |
| Current smoker                |         | 179 (53.4)   | 244 (56.0)   | 0.444   |
| Ex-smoker                     |         | 66 (19.7)    | 91 (20.9)    |         |
| Nonsmoker                     |         | 87 (26.0)    | 97 (22.2)    |         |
| Total energy intake (kcal)    |         | 1819 ± 1534  | 1815 ± 529   | 0.919   |
| Total fat intake (% of energy)|         | 26.2 ± 6.8   | 25.6 ± 6.7   | 0.192   |
| Omega-3 fatty acid intake (% of energy) | | | | |
| α-LA intake (C18:3n-3)         |         | 0.93 ± 0.30  | 0.86 ± 0.30  | 0.002   |
| Octadecatetraenoic acid intake (C18:4n-3) | | 0.04 ± 0.02 | 0.03 ± 0.02 | 0.375 |
| Eicosatetraenoic acid intake (C20:4n-3) | | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.361 |
| Eicosapentaenoic acid intake (C20:5n-3) | | 0.16 ± 0.09 | 0.16 ± 0.10 | 0.364 |
| Docosapentaenoic acid intake (C22:5n-3) | | 0.04 ± 0.02 | 0.04 ± 0.03 | 0.459 |
| Docosahexaenoic acid intake (C22:6n-3) | | 0.28 ± 0.14 | 0.27 ± 0.15 | 0.372 |
| Docosahexaenoic acid and eicosapentaenoic acid intake | | 0.45 ± 0.23 | 0.43 ± 0.24 | 0.367 |
| Total omega-3 fatty acid intake | | 1.52 ± 0.47 | 1.43 ± 0.48 | 0.013 |

aHADS-D: Depression subscale of the Hospital Anxiety and Depression Scale. bDefined by TNM classification: International Union Against Cancer. cDefined by the Eastern Cooperative Oncology Group.

© 2004 Cancer Research UK
Table 2  Odds ratio of depression according to quartiles of omega-3 fatty acids intake (% energy) by the lung cancer patients (*n* = 771)

| Median Intake (% energy) | ≤ 4 n (%) | ≥ 5 n (%) | Crude | Adjusted for age and sex (95% CI) | Multivariate b |
|--------------------------|-----------|-----------|-------|----------------------------------|----------------|
| Quartiles of α-linolenic acid intake (C18:3n-3) | | |       |                                  |                |
| q1                      | 0.552     | 68 (35.4) | 124 (64.6) | 1.00 | 1.00 | 1.00 |
| q2                      | 0.776     | 80 (41.5) | 113 (58.5) | 0.78 (0.51 – 1.17) | 0.76 (0.50 – 1.15) | 0.68 (0.43 – 1.07) |
| q3                      | 0.982     | 93 (48.2) | 100 (51.8) | 0.59 (0.39 – 0.89) | 0.56 (0.37 – 0.85) | 0.55 (0.34 – 0.87) |
| q4                      | 1.223     | 94 (48.7) | 99 (51.3) | 0.58 (0.38 – 0.87) | 0.54 (0.35 – 0.82) | 0.50 (0.31 – 0.71) |
| P for trend              |           |           |           | 0.004 | 0.002 | 0.004 |
| Quartiles of octadecatetraenoic acid intake (C18:4n-3) | | |       |                                  |                |
| q1                      | 0.015     | 71 (40.0) | 121 (60.0) | 1.00 | 1.00 | 1.00 |
| q2                      | 0.024     | 83 (43.0) | 110 (57.0) | 0.78 (0.52 –1.17) | 0.78 (0.52 –1.18) | 0.72 (0.46 –1.13) |
| q3                      | 0.034     | 96 (49.7) | 97 (50.3) | 0.59 (0.40 –0.89) | 0.58 (0.39 –0.88) | 0.61 (0.40 –0.95) |
| q4                      | 0.062     | 85 (44.0) | 108 (56.0) | 0.75 (0.50 –1.12) | 0.74 (0.49 –1.13) | 0.83 (0.53 –1.30) |
| P for trend              |           |           |           | 0.250 | 0.250 | 0.721 |
| Quartiles of eicosapentaenoic acid intake (C20:5n-3) | | |       |                                  |                |
| q1                      | 0.008     | 75 (39.1) | 117 (60.9) | 1.00 | 1.00 | 1.00 |
| q2                      | 0.001     | 81 (42.0) | 112 (58.0) | 0.89 (0.59 –1.33) | 0.89 (0.59 –1.34) | 0.88 (0.57 –1.36) |
| q3                      | 0.017     | 97 (50.3) | 96 (49.7) | 0.63 (0.42 –0.95) | 0.64 (0.42 –0.95) | 0.63 (0.41 –0.97) |
| q4                      | 0.027     | 82 (42.5) | 111 (57.5) | 0.87 (0.58 –1.30) | 0.86 (0.57 –1.30) | 0.97 (0.62 –1.51) |
| P for trend              |           |           |           | 0.434 | 0.409 | 0.864 |
| Quartiles of docosapentaenoic acid intake (C22:5n-3) | | |       |                                  |                |
| q1                      | 0.020     | 75 (39.1) | 117 (60.9) | 1.00 | 1.00 | 1.00 |
| q2                      | 0.032     | 82 (42.5) | 111 (57.5) | 0.87 (0.58 –1.30) | 0.88 (0.58 –1.32) | 0.88 (0.57 –1.36) |
| q3                      | 0.054     | 91 (47.2) | 102 (52.8) | 0.71 (0.47 –1.06) | 0.69 (0.46 –1.04) | 0.55 (0.42 –1.01) |
| q4                      | 0.074     | 85 (44.0) | 108 (56.0) | 0.87 (0.58 –1.30) | 0.86 (0.57 –1.30) | 0.99 (0.64 –1.55) |
| P for trend              |           |           |           | 0.332 | 0.312 | 0.849 |
| Quartiles of docosahexaenoic acid intake (22:6n-3) | | |       |                                  |                |
| q1                      | 0.140     | 74 (38.5) | 118 (61.5) | 1.00 | 1.00 | 1.00 |
| q2                      | 0.206     | 82 (42.5) | 111 (57.5) | 0.85 (0.57 –1.28) | 0.86 (0.57 –1.30) | 0.95 (0.61 –1.47) |
| q3                      | 0.290     | 93 (48.2) | 100 (51.8) | 0.67 (0.45 –1.01) | 0.67 (0.44 –1.00) | 0.60 (0.38 –0.93) |
| q4                      | 0.435     | 86 (44.6) | 107 (55.4) | 0.78 (0.52 –1.17) | 0.77 (0.51 –1.17) | 0.94 (0.60 –1.47) |
| P for trend              |           |           |           | 0.218 | 0.197 | 0.556 |
| Quartiles of Total omega-3 fatty acid intake | | |       |                                  |                |
| q1                      | 0.943     | 67 (34.9) | 125 (65.1) | 1.00 | 1.00 | 1.00 |
| q2                      | 1.275     | 87 (45.1) | 106 (54.9) | 0.65 (0.43 –0.99) | 0.63 (0.42 –0.96) | 0.63 (0.40 –0.99) |
| q3                      | 1.603     | 86 (44.6) | 107 (55.4) | 0.67 (0.44 –1.01) | 0.64 (0.42 –0.97) | 0.61 (0.38 –0.97) |
| q4                      | 2.007     | 95 (49.2) | 98 (50.8) | 0.55 (0.37 –0.83) | 0.52 (0.34 –0.80) | 0.55 (0.35 –0.88) |
| P for trend              |           |           |           | 0.008 | 0.005 | 0.022 |
| Quartiles of sum eicosapentaenoic and docosahexaenoic acid intake | | |       |                                  |                |
| q1                      | 0.217     | 76 (39.6) | 116 (60.4) | 1.00 | 1.00 | 1.00 |
| q2                      | 0.322     | 79 (40.9) | 114 (59.1) | 0.95 (0.63 –1.42) | 0.96 (0.64 –1.44) | 1.00 (0.65 –1.56) |
| q3                      | 0.456     | 94 (48.7) | 99 (51.3) | 0.69 (0.46 –1.03) | 0.68 (0.45 –1.02) | 0.64 (0.41 –0.98) |
| q4                      | 0.700     | 86 (44.6) | 107 (55.4) | 0.82 (0.54 –1.22) | 0.81 (0.54 –1.22) | 0.96 (0.61 –1.49) |
| P for trend              |           |           |           | 0.237 | 0.221 | 0.648 |

*HADS-D: Depression subscale of the Hospital Anxiety and Depression Scale. bAdjusted for age, sex, performance status, clinical stage, histology, pain, breathlessness, employment, smoking, alcohol consumption, and body mass index as covariates. 95% confidence interval.*
Omega-3 fatty acid and cancer patients’ depression
S Suzuki et al

Depression and ω-3 FA intake

Of the 771 patients analysed, 436 patients (56.5%) had depression (Table 1).

The crude odds ratio for depression among patients in the highest quartile of the total EDA and DHA intake was 0.82 (95% CI 0.54 – 1.22) compared with patients in the lowest quartile, and the adjusted odds ratio after controlling for possibly associated factors was 0.96 (95% CI 0.61 – 1.49); no significant trend in the odds ratios for depression was observed with regard to total EDA and DHA intake (P for trend = 0.648, Table 2 and Figure 1). No significant negative association was found between either EPA intake or DHA intake and depression (EPA: adjusted odds ratio = 0.99, 95% CI: 0.64 – 1.55, P for trend = 0.849; DHA: adjusted odds ratio = 0.94, 95% CI: 0.60 – 1.47, P for trend = 0.584).

The crude odds ratio for depression among patients in the highest quartile of ω-3 FA intake was 0.58 (95% CI 0.38 – 0.87) compared with patients in the lowest quartile, and the adjusted odds ratio after controlling for the possibly associated factors was 0.50 (95% CI 0.31 – 0.71); a significant trend in the odds ratio for depression was observed with regard to total ω-3 FA intake (P for trend = 0.004, Table 2 and Figure 1). A significant negative association was also found between total ω-3 FA intake and depression (crude odds ratio = 0.55, 95% CI: 0.37 – 0.83, P for trend = 0.008; adjusted odds ratio = 0.55, 95% CI: 0.35 – 0.88, P for trend = 0.022). In addition, we performed the same analysis for 786 subjects including subjects whose answers were regarded as indicating an extremely low caloric intake (below 900 kcal day⁻¹ in men or below 800 kcal day⁻¹ in women, n = 15), since it was impossible to discount the possibility that those patients may have had a low caloric intake for a variety of reasons (e.g., chronic depression). The results of this analysis were similar to the previously obtained results (data not shown).

No association between depression and the intake of fish and seafood was observed (adjusted OR = 0.81, 95% CI: 0.52 – 1.26, P for trend = 0.285, Table 3).

DISCUSSION

This report is the first cross-sectional study to investigate the association between dietary ω-3 FA intake, as calculated using FFQ data, and the prevalence of depression among cancer patients. Inconsistent with the results of a previous epidemiological study, we did not observe a significant association between total DHA and EPA intake and the prevalence of depression in newly diagnosed patients with lung cancer. This finding suggests that DHA and EPA intake may not contribute to a susceptibility to depression among Japanese cancer patients. Since the standard Japanese diet contains larger amounts of fish than the diets of Europeans or Americans, the antidepressive effect of DHA and EPA may not be apparent in our sample. Another possible reason for the discrepancy in findings is that the characteristics of depression in this study may differ from those of previous studies.

Previous epidemiological research examined the prevalence of depression in the general population (Hibbeln, 1998; Tanskanen et al, 2001), while we examined depression among a population that was subjected to the stress of having recently been diagnosed with lung cancer. Thus, differences in the situations of the subjects may have caused the inconsistent findings. In addition, our results must be interpreted with caution, because our sample size was smaller than that of previous epidemiological studies.

Interestingly, a significant inverse dose–response relationship was observed between ω-3 or total ω-3 FA intake and the prevalence of depression. To the best of our knowledge, this is one of the first clinical reports to demonstrate an association between ω-3 FA intake and depression (see Rudin (1981) for a case report).

Although the present study has a cross-sectional design, preventing us from making any conclusions as to the causality of ω-3 FA intake and depression, it seemed unlikely that depression would change the intake of ω-3 FA. In the present study, no significant differences in total caloric intake and total fat intake were found between patients with depression and those without (Table 1). Our results suggest that low levels of ω-3 FA or total ω-3 FA intake may contribute to a susceptibility to depression. A further clinical trial using supplements or a special diet is needed to clarify the independent effects of each ω-3 FA on depression.

ω-Linolenic acid intake is known to have an influence on the fundamental structural and functional roles in the developing and mature nervous system (Bourre et al, 1993; Uauy et al, 1996), and
Table 3  Odds ratio of depression according to quartiles of fish intake (g per 1000 kcal) by the lung cancer patients (n = 771)

| Quartile | Median intake (g per 1000 kcal) | ≤ 4 n (%) | ≥ 5 n (%) | Odds ratio Crude | Adjusted for age and sex 95% CI | Multivariate 95% CI |
|----------|---------------------------------|-----------|-----------|-----------------|-------------------------------|------------------|
| q1       | 20.5                            | 77 (40.1) | 115 (59.9)| 1.00            | 1.00                          | 1.00             |
| q2       | 32.3                            | 80 (41.5) | 113 (58.5)| 0.95 (0.63–1.42)| 0.94 (0.62–1.42)               | 0.96 (0.62–1.50) |
| q3       | 44.4                            | 87 (45.1) | 106 (54.9)| 0.82 (0.54–1.22)| 0.81 (0.54–1.21)               | 0.79 (0.51–1.23) |
| q4       | 67.0                            | 91 (47.2) | 102 (52.8)| 0.75 (0.50–1.12)| 0.73 (0.49–1.11)               | 0.81 (0.52–1.26) |

P for trend 0.127 0.107 0.285

HADS-D*  Depression subscale of the Hospital Anxiety and Depression Scale. Adjusted for age, sex, performance status, clinical stage, histology, pain, breathlessness, employment, smoking, alcohol consumption, and body mass index as covariates. 95% confidence interval.

an interaction between ω-3 FA intake and neurotransmitters has been observed in animal experiments (Delion et al., 1996). ω-3 Linolenic acid may influence depression via a mechanism that is different from that of DHA or EPA. Another possibility is that the total ω-3 FA (including ω-3 LA) intake may reflect the concentration of DHA and EPA in the body or brain, rather than the sum of EPA and DHA intake only, since ω-3 LA is the main source of ω-3 FA in the diet and can be converted into DHA or EPA in humans. Further investigation of a specific ω-3 FA biomarker is needed to confirm this speculation.

Our study has several limitations. First, a sampling bias was present in the data because all of the subjects attended a single institution and thus were not representative of lung cancer patients in general. Second, their possibility of a selection bias should be considered, since we did not have data on approximately 20% of the potentially eligible patients and the analysed subjects had a relatively better PS, an earlier clinical stage, and were younger than the nonanalysed subjects. Third, since only lung cancer patients who had been informed of their diagnosis but had not yet started their cancer treatment were included in the study, the results may not be applicable to other cancer patients and other cancer settings. Fourth, we used a self-administered questionnaire to evaluate ω-3 FA intake because a large sample of patients was needed for The Lung Cancer Database Project. The data obtained from the FFQ may not reflect the actual ω-3 FA intake as accurately as other more detailed methods, such as dietary records. Fifth, we did not use a structured psychiatric interview in this study (such as the Structured Clinical Interview for DSM-IV, a widely recognized standard). However, HADS has been shown to be reliable and valid for the screening of depression in patients with cancer (Razavi et al., 1990; Hopwood et al., 1991), and is widely used in the field of oncology (Patrick et al., 2003). Finally, a causal relationship between ω-3 FA intake and depression cannot be confirmed, because of the cross-sectional design of this study. To clarify the independent effects of each ω-3 FA on depression, a further clinical trial using supplements or a special diet is needed.

In conclusion, we did not observe a significant relationship between total EPA and DHA intake and depression in newly diagnosed Japanese patients with lung cancer, but significant inverse relationships between ω-3 LA intake or total ω-3 FA intake and depression were noted. Our findings suggest that EPA and DHA may be of little use as an antidepressant in Japanese cancer patients. However, the association between ω-3 LA intake or total ω-3 FA intake and depression should be further investigated. To elucidate the association between each ω-3 FA and depression in patients with cancer, further clinical research (including the examination of specific biomarkers) is needed.

ACKNOWLEDGEMENTS
We would like to express special thanks to Ms Toyoko Matsumoto for the collecting and filing the data for the study, and to Dr Tomoyuki Hanaoka MD, PhD, and Professor Tomohito Hamazaki MD, PhD for general comments about this study. We also wish to thank the entire staff of Psycho-Oncology Division for their helpful advice. This work was supported by a Grant-in-Aid for Cancer Research and Second-Term Comprehensive 10-Year Strategy for Cancer Control and Research of the Japanese Ministry of Health, Labour, and Welfare.

REFERENCES
Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y (2002) Predictive factors for suicidal ideation in patients with unresectable lung carcinoma. Cancer 95: 1085–1093
Akiyama N, Okamura H, Akechi T, Nakano T, Yoshikawa E, Nakanishi T, Uchitomi Y (2002) Clinical experience of the pharmacological treatment algorithm for major depression in advanced cancer patients: preliminary study. Int J Psychiatry Clin Pract 6: 83 – 89
Bourre JM, Bonnell M, Clement M, Dumont O, Durand G, Lafont H, Nabone G, Piccitti M (1993) Function of dietary polyunsaturated fatty acids in the nervous system. Prostagland Leukot Essent Fatty Acids 48: 5 – 15
Breitbart W, Rosenfeld B, Pessin H, Kaim M, Funesti-Eschi J, Galieta M, Nelson CJ, Brescia R (2000) Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 284: 2907 – 2911
Chiu CG, Huang SY, Shen WW, Su KP (2003) Omega-3 fatty acids for depression in pregnancy. Am J Psychiatry 160: 385
Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A (2000) Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 356: 1326 – 1327
Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G (1996) alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotonergic neurotransmission in the rat frontal cortex. J Neurochem 66: 1582 – 1591
Edwards R, Peet M, Shay J, Horrobin D (1998) Omega-3 polynsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 48: 149 – 155
Gill D, Hatcher S (1999) A systematic review of the treatment of depression with antidepressant drugs in patients who also have a physical illness. J Psychosom Res 47: 131 – 143

British Journal of Cancer (2004) 90(4), 787 – 793 © 2004 Cancer Research UK
Grassi L, Indelli M, Marzola M, Maestri A, Santini A, Pirva E, Boccalon M (1996) Depressive symptoms and quality of life in home-care-assisted cancer patients. *J Pain Symptom Manage* 12: 300 – 307

Hibbeln JR (1998) Fish consumption and major depression. *Lancet* 351: 1213

Hibbeln JR, Salem Jr N (1995) Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. *Am J Clin Nutr* 62: 1 – 9

Hopwood P, Howell A, Maguire P (1991) Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. *Br J Cancer* 64: 353 – 356

Kugaya A, Akechi T, Okuyama T, Okamura H, Uchitomi Y (1998) Screening for psychological distress in Japanese cancer patients. *Jpn J Clin Oncol* 28: 333 – 338

Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY (1999) Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesterol esters of depressed patients. *Psychiatry Res* 85: 275 – 291

Maes M, Smith RS (1998) Fatty acids, cytokines, and major depression. *Biol Psychiatry* 43: 313 – 314

Massie MJ, Popkin MK (1998) Depressive disorder. In *Psycho-Oncology*, Holland JC (ed) pp 518 – 540. New York: Oxford University Press

McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB (1995) Depression in patients with cancer. Diagnosis, biology, and treatment. *Arch Gen Psychiatry* 52: 89 – 99

Nemets B, Stahl Z, Belmaker RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. *Am J Psychiatry* 159: 477 – 479

Patrick DL, Ferketic SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Ried LD, Turrissi III AT, Unutzer J, Vernon SW (2003) National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15 – 17, 2002. *J Natl Cancer Inst* 95: 1110 – 1117

Pawlowsky RJ, Salem Jr N (1999) Alcohol consumption in rhesus monkeys depletes tissues of polyunsaturated fatty acids and alters essential fatty acid metabolism. *Alcohol Clin Exp Res* 23: 311 – 317

Peet M, Horrobin DF (2002) A dose-ranging study of the effects of eicosapentaenoic acid in patients with ongoing depression despite apparently adequate treatment with standard drugs. *Arch Gen Psychiatry* 59: 913 – 919

Peet M, Murphy B, Shay J, Horrobin D (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. *Biol Psychiatry* 43: 315 – 319

Puri BK, Counsell SJ, Richardson AJ, Horrobin DF (2002) Eicosapentaenoic acid in treatment-resistant depression. *Arch Gen Psychiatry* 59: 91 – 92

Razavi D, Delvaux N, Farvacques C, Robaye E (1990) Screening for adjustment disorders and major depressive disorders in cancer inpatients. *Br J Psychiatry* 156: 79 – 83

Rudin DO (1981) The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. *Biol Psychiatry* 16: 837 – 850

Sasaki S, Kobayashi M, Ishihara J, Tsugane S (2003) Self-administered food frequency questionnaire used in the 5-year follow-up survey of the JPHC study: questionnaire structure, computation algorithms, and area-based mean intake. *J Epidemiol* 13(Suppl): S13 – S22

Sasaki S, Kobayashi M, Tsugane S (1999) Development of substituted fatty acid food composition table for the use in nutritional epidemiologic studies for Japanese populations: its methodological background and the evaluation. *J Epidemiol* 9: 190 – 197

Science and Technology Agency (1999) *Fatty Acids, Cholesterol, Vitamin E Composition Table of Japanese Foods*. Tokyo: Ishiyaku Shuppan Publishers (in Japanese)

Simon JA, Fong J, Bernert Jr JT, Browner WS (1996) Relation of smoking and alcohol consumption to serum fatty acids. *Am J Epidemiol* 144: 325 – 334

Smith RS (1991) The macrophage theory of depression. *Med Hypotheses* 35: 298 – 306

Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. *Arch Gen Psychiatry* 56: 407 – 412

Tanskanen A, Hibbeln JR, Tuomilehto J, Uutela A, Hakkkala A, Viinamaki H, Lehtonen J, Vartiainen E (2001) Fish consumption and depressive symptoms in the general population in Finland. *Psychiatr Serv* 52: 529 – 531

Tsubono Y, Takamori S, Kobayashi M, Takahashi T, Iwase Y, Itoi Y, Akabane M, Yamaguchi M, Tsugane S (1996) A data-based approach for designing a semiquantitative food frequency questionnaire for a population-based prospective study in Japan. *J Epidemiol* 6: 45 – 53

Uauy R, Peirano P, Hoffman D, Mena P, Birch D, Birch E (1996) Role of essential fatty acids in the function of the developing nervous system. *Lipids* 31(Suppl): S167 – S176

Zanarini MC, Frankenburg FR (2003) Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. *Am J Psychiatry* 160: 167 – 169

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. *Acta Psychiatr Scand* 67: 361 – 370